APA Citation

Raedler, L. A. (2015). Keytruda (Pembrolizumab): First PD-1 Inhibitor Approved for Previously Treated Unresectable or Metastatic Melanoma. Am Health Drug Benefits.

Citação norma Chicago

Raedler, Lisa A. "Keytruda (Pembrolizumab): First PD-1 Inhibitor Approved for Previously Treated Unresectable or Metastatic Melanoma." Am Health Drug Benefits 2015.

MLA Citation

Raedler, Lisa A. "Keytruda (Pembrolizumab): First PD-1 Inhibitor Approved for Previously Treated Unresectable or Metastatic Melanoma." Am Health Drug Benefits 2015.

Advarsel: Disse citationer er muligvist ikke 100% nøjagtige.